Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407

Paz-Ares, L.Vicente, D.Tafreshi, A.Robinson, A.Soto Parra, H.Mazieres, J.Hermes, B.2024-06-122024-06-1220190923-75341569-8041https://hdl.handle.net/20.500.14551/2679944th Congress of the European-Society-for-Medical-Oncology (ESMO) -- SEP 27-OCT 01, 2019 -- Barcelona, SPAIN[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Pembrolizumab (pembro) 1 chemotherapy (chemo) in metastatic squamous NSCLC: Final analysis and progression after the next line of therapy (PFS2) in KEYNOTE-407Conference Object30Q1WOS:000491295500206